Cellnovo Gets Early Foothold In US Diabetes Market With TypeZero Partnership
Executive Summary
Cellnovo's partnership with US start-up TypeZero Technologies and its participation in an upcoming international artificial pancreas trial will allow the company to gain an early foothold in the US market before seeking FDA clearance for its diabetes management system, said to be the first and only one of its kind to have an insulin patch pump with mobile connectivity features.